Drug Profile


Alternative Names: RDC5

Latest Information Update: 11 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chronos Therapeutics
  • Class Neuroprotectants; Osteoporosis therapies
  • Mechanism of Action Autophagy stimulants; Reactive oxygen species modulators; Synuclein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders; Obesity

Highest Development Phases

  • Phase I Neurodegenerative disorders
  • Preclinical Obesity
  • Discontinued Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 11 May 2016 RDC 5 is available for licensing as of 11 May 2016. http://chronostherapeutics.com/
  • 11 May 2016 Discontinued - Phase-I for Osteoporosis in United Kingdom (PO)
  • 11 May 2016 Discontinued - Preclinical for Postmenopausal osteoporosis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top